Literature DB >> 27412728

Mitochondrial Oxidative Phosphorylation System (OXPHOS) Deficits in Schizophrenia: Possible Interactions with Cellular Processes.

Oded Bergman1, Dorit Ben-Shachar2.   

Abstract

Mitochondria are key players in the generation and regulation of cellular bioenergetics, producing the majority of adenosine triphosphate molecules by the oxidative phosphorylation system (OXPHOS). Linked to numerous signaling pathways and cellular functions, mitochondria, and OXPHOS in particular, are involved in neuronal development, connectivity, plasticity, and differentiation. Impairments in a variety of mitochondrial functions have been described in different general and psychiatric disorders, including schizophrenia (SCZ), a severe, chronic, debilitating illness that heavily affects the lives of patients and their families. This article reviews findings emphasizing the role of OXPHOS in the pathophysiology of SCZ. Evidence accumulated during the past few decades from imaging, transcriptomic, proteomic, and metabolomic studies points at OXPHOS deficit involvement in SCZ. Abnormalities have been reported in high-energy phosphates generated by the OXPHOS, in the activity of its complexes and gene expression, primarily of complex I (CoI). In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ. Finally, CoI has been shown as a site of interaction for both dopamine (DA) and antipsychotic drugs, further substantiating its role in the pathology of SCZ. Understanding the role of mitochondria and the OXPHOS in particular may encourage new insights into the pathophysiology and etiology of this debilitating disorder.
© The Author(s) 2016.

Entities:  

Keywords:  Schizophrenia; cAMP/PKA and Ca+2 signaling; complex I; dopamine; mitochondria; neurodevelopment and plasticity; oxidative phosphorylation system

Mesh:

Year:  2016        PMID: 27412728      PMCID: PMC4959648          DOI: 10.1177/0706743716648290

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  196 in total

1.  Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia.

Authors:  I Maurer; S Zierz; H Möller
Journal:  Schizophr Res       Date:  2001-03-01       Impact factor: 4.939

Review 2.  Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.

Authors:  S Kapur; G Remington
Journal:  Biol Psychiatry       Date:  2001-12-01       Impact factor: 13.382

Review 3.  Regulation of mitochondrial respiration and apoptosis through cell signaling: cytochrome c oxidase and cytochrome c in ischemia/reperfusion injury and inflammation.

Authors:  Maik Hüttemann; Stefan Helling; Thomas H Sanderson; Christopher Sinkler; Lobelia Samavati; Gargi Mahapatra; Ashwathy Varughese; Guorong Lu; Jenney Liu; Rabia Ramzan; Sebastian Vogt; Lawrence I Grossman; Jeffrey W Doan; Katrin Marcus; Icksoo Lee
Journal:  Biochim Biophys Acta       Date:  2011-07-13

4.  CSF calcium: clinical correlates in affective illness and schizophrenia.

Authors:  D C Jimerson; R M Post; J S Carman; D P van Kammen; J H Wood; F K Goodwin; W E Bunney
Journal:  Biol Psychiatry       Date:  1979-02       Impact factor: 13.382

5.  Mitochondrial DNA HV lineage increases the susceptibility to schizophrenia among Israeli Arabs.

Authors:  Shirly Amar; Alon Shamir; Ofer Ovadia; Monica Blanaru; Alon Reshef; Ilana Kremer; Marcella Rietschel; Thomas G Schulze; Wolfgang Maier; R H Belmaker; Richard P Ebstein; Galila Agam; Dan Mishmar
Journal:  Schizophr Res       Date:  2007-06-12       Impact factor: 4.939

6.  Chapter 6 Mass spectrometric characterization of the thirteen subunits of bovine respiratory complexes that are encoded in mitochondrial DNA.

Authors:  John E Walker; Joe Carroll; Matthew C Altman; Ian M Fearnley
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

7.  Brain metabolic alterations in medication-free patients with bipolar disorder.

Authors:  Stephen R Dager; Seth D Friedman; Aimee Parow; Christina Demopulos; Andrew L Stoll; In Kyoon Lyoo; David L Dunner; Perry F Renshaw
Journal:  Arch Gen Psychiatry       Date:  2004-05

8.  Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons.

Authors:  Diane T W Chang; Gordon L Rintoul; Sruthi Pandipati; Ian J Reynolds
Journal:  Neurobiol Dis       Date:  2006-02-09       Impact factor: 5.996

Review 9.  Axonal regeneration in adult CNS neurons--signaling molecules and pathways.

Authors:  Felicia Yu Hsuan Teng; Bor Luen Tang
Journal:  J Neurochem       Date:  2006-02-10       Impact factor: 5.372

Review 10.  cAMP and mitochondria.

Authors:  Federica Valsecchi; Lavoisier S Ramos-Espiritu; Jochen Buck; Lonny R Levin; Giovanni Manfredi
Journal:  Physiology (Bethesda)       Date:  2013-05
View more
  38 in total

Review 1.  Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.

Authors:  L Holper; D Ben-Shachar; J J Mann
Journal:  Neuropsychopharmacology       Date:  2018-05-16       Impact factor: 7.853

2.  NDUFV2 pseudogene (NDUFV2P1) contributes to mitochondrial complex I deficits in schizophrenia.

Authors:  Oded Bergman; Rachel Karry; Jumana Milhem; Dorit Ben-Shachar
Journal:  Mol Psychiatry       Date:  2018-12-10       Impact factor: 15.992

3.  Energization by multiple substrates and calcium challenge reveal dysfunctions in brain mitochondria in a model related to acute psychosis.

Authors:  Jamila Monteiro; Gabriela Assis-de-Lemos; Eduardo de-Souza-Ferreira; Adriana M Marques; Gilda A Neves; Mariana S Silveira; Antonio Galina
Journal:  J Bioenerg Biomembr       Date:  2019-12-18       Impact factor: 2.945

4.  Mitochondrial Dysfunction in Psychiatric Illness.

Authors:  Rebecca Anglin
Journal:  Can J Psychiatry       Date:  2016-08       Impact factor: 4.356

Review 5.  The bimodal mechanism of interaction between dopamine and mitochondria as reflected in Parkinson's disease and in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2019-12-17       Impact factor: 3.575

6.  Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence.

Authors:  Brandi L Rollins; Ling Morgan; Brooke E Hjelm; Adolfo Sequeira; Alan F Schatzberg; Jack D Barchas; Francis S Lee; Rick M Myers; Stanley J Watson; Huda Akil; Steven G Potkin; William E Bunney; Marquis P Vawter
Journal:  Mol Neuropsychiatry       Date:  2017-11-30

7.  Synaptic Proteome Alterations in the Primary Auditory Cortex of Individuals With Schizophrenia.

Authors:  Matthew L MacDonald; Megan Garver; Jason Newman; Zhe Sun; Joseph Kannarkat; Ryan Salisbury; Jill Glausier; Ying Ding; David A Lewis; Nathan Yates; Robert A Sweet
Journal:  JAMA Psychiatry       Date:  2020-01-01       Impact factor: 21.596

8.  Abnormalities in High-Energy Phosphate Metabolism in First-Episode Bipolar Disorder Measured Using 31P-Magnetic Resonance Spectroscopy.

Authors:  Fei Du; Cagri Yuksel; Virginie-Anne Chouinard; Polly Huynh; Kyle Ryan; Bruce M Cohen; Dost Öngür
Journal:  Biol Psychiatry       Date:  2017-04-07       Impact factor: 13.382

9.  iTRAQ-Based Quantitative Proteomics Suggests Synaptic Mitochondrial Dysfunction in the Hippocampus of Rats Susceptible to Chronic Mild Stress.

Authors:  Hong Xie; Haojun Huang; Min Tang; Yan Wu; Rongzhong Huang; Zhao Liu; Mi Zhou; Wei Liao; Jian Zhou
Journal:  Neurochem Res       Date:  2018-10-22       Impact factor: 3.996

Review 10.  Psychiatric drugs impact mitochondrial function in brain and other tissues.

Authors:  Shawna T Chan; Michael J McCarthy; Marquis P Vawter
Journal:  Schizophr Res       Date:  2019-11-16       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.